Despite the fact that more than a third of U.S. adults are obese, it's been an uphill battle for developers of obesity treatments.» Read More
U.S. bonds fell back on Wednesday, as the previous session's stock market rally caused investors' bid for "safe-haven" assets to wane.
U.S. stock index futures traded higher on Wednesday, ahead of a busy day for bank, tech and pharmaceutical earnings.
*Novartis reviewing fate of animal health, vaccines and OTC units. BASEL, Switzerland, March 20- Novartis Chief Executive Joe Jimenez is taking a hard look at the drugmaker's smaller businesses as he reshapes the company for what he expects to be a "brutal" new era in healthcare spending.
*Market leader Abbott, others still investing in India. *GlaxoSmithKline spends $1 bln to raise India unit stake. The two top foreign players, Abbott Laboratories and GlaxoSmithKline Plc, are actually stepping up investment, and others such as AstraZeneca Plc are considering doing so.
It's a long play, but emerging markets promise significant growth for the health-care industry, said Abbott CFO Thomas Freyman.
SAN FRANCISCO, March 10- A U.S. appeals court ruling that significantly boosted gay rights will stand, as a pharmaceutical company involved in the case said on Monday that it would not appeal.
"The world is going to want to find a compromise," said David Kelly, chief market strategist at J.P. Morgan Funds.
NEW YORK, March 3- Russia's military move on the Crimean peninsula has raised tensions between Moscow and the West to levels not seen since the Cold War ended, but U.S. investors are not yet ready to sell, duck or cover.
Wednesday's midday movers:
What 10 stocks does trader Michael Farr think are going to deliver in 2014? Click ahead to find out.
It’s time for the Lightning Round. Cramer makes the call on viewer favorites.
Westwood Holding Group’s Mark Freeman has investment recommendations for companies less dependent on Fed stimulus.
Has Washington distracted you from these money making developments?
Take a look at some of Wednesday's midday movers:
U.S. stock index futures pointed to a higher open on Wednesday, with lawmakers looking to strike a deal to lift the country's borrowing limit before Thursday's deadline.
With a deadline hanging over Congress, stocks could be whipped by headlines from Washington but should ultimately be able to limp through the drama.
On the heels of Microsoft boosting its dividend and renewing its buyback, there are a host of other companies that could be candidates for the same.
We could be witnessing the beginning of a merger wave in biotech, Jim Cramer said Tuesday.
China fined six companies including New Zealand dairy giant Fonterra a total of $110 million following an investigation into price fixing and anti-competitive practices by foreign baby formula makers.
Pfizer reported earnings slightly ahead of forecasts, as the largest U.S. drugmaker lines up a business split that could lead to the spin-off of its generics division.